Sinovac Biotech LTD (SVA) — SEC Filings

Overview

Sinovac Biotech LTD (SVA) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 6-K filed on Dec 17, 2025: Sinovac Biotech Ltd. filed a Form 6-K on January 30, 2026, reporting for the month of December 2025. The filing indicates the company's principal executive offices are located at No. 39 Shangdi Xi Road, Haidian District, Beijing, People's Republic of China. The company is registered under SEC file n

Sentiment Summary

Across 28 filings, the sentiment breakdown is: 1 bearish, 27 neutral. The dominant filing sentiment for Sinovac Biotech LTD is neutral.

Filing Type Overview

Sinovac Biotech LTD (SVA) has filed 24 6-K, 2 SC 13D/A, 1 20-F, 1 SC 13G/A with the SEC between Feb 2024 to Dec 2025.

Recent Filings (28)

• Sinovac Biotech Ltd. Files December 2025 6-K Report — 6-K · Dec 17, 2025 Risk: low
  Sinovac Biotech Ltd. filed a Form 6-K on January 30, 2026, reporting for the month of December 2025. The filing indicates the company's principal executive offi
• Sinovac Biotech Ltd. Files 6-K Report — 6-K · Nov 20, 2025 Risk: low
  Sinovac Biotech Ltd. filed a Form 6-K on November 20, 2025, for the month of November 2025. The report is for a foreign private issuer and indicates the company
• Sinovac Biotech Ltd. Files November 2025 6-K Report — 6-K · Nov 5, 2025 Risk: low
  Sinovac Biotech Ltd. filed a Form 6-K on November 5, 2025, reporting for the month of November 2025. The company, headquartered in Beijing, China, is a pharmace
• Sinovac Biotech Ltd. Board Approves Matters in August 2025 Filing — 6-K · Aug 21, 2025 Risk: low
  Sinovac Biotech Ltd. announced on August 19, 2025, that its Board of Directors approved certain matters. The company, a biopharmaceutical provider in China, fil
• Sinovac Biotech Ltd. Files Form 6-K — 6-K · Jul 11, 2025 Risk: low
  Sinovac Biotech Ltd. filed a Form 6-K on July 11, 2025, reporting for the month of July 2025. The filing includes a press release as Exhibit 99.1. The company's
• Sinovac Biotech Ltd. Files Form 6-K — 6-K · Jul 10, 2025 Risk: low
  Sinovac Biotech Ltd. filed a Form 6-K on July 10, 2025, reporting for the month of July 2025. The filing was signed by Dr. Chiang Li, Chairman of the Board, ind
• Sinovac Biotech Files July 2025 6-K Report — 6-K · Jul 8, 2025 Risk: low
  Sinovac Biotech Ltd. filed a Form 6-K on July 8, 2025, reporting for the month of July 2025. The filing includes an Exhibit 99.1, but the specific content of th
• Sinovac Biotech Ltd. Files July 2025 6-K Report — 6-K · Jul 2, 2025 Risk: low
  Sinovac Biotech Ltd. filed a Form 6-K on July 2, 2025, for the month of July 2025. The filing indicates that Dr. Chiang Li, Chairman of the Board, has signed on
• Sinovac Biotech Ltd. Files June 2025 6-K Report — 6-K · Jun 30, 2025 Risk: low
  Sinovac Biotech Ltd. filed a Form 6-K on June 30, 2025, for the month of June 2025. The filing is a report of a foreign private issuer and indicates that the co
• Sinovac Biotech Ltd. Files June 2025 6-K Report — 6-K · Jun 25, 2025 Risk: low
  Sinovac Biotech Ltd. filed a Form 6-K on June 25, 2025, reporting for the month of June 2025. The filing indicates the company's principal executive offices are
• Sinovac Biotech Files Routine 6-K Report — 6-K · Jun 20, 2025 Risk: low
  Sinovac Biotech Ltd. filed a Form 6-K on June 20, 2025, for the month of June 2025. The filing was signed by Dr. Chiang Li, Chairman of the Board, indicating th
• Sinovac Biotech Files June 2025 Report — 6-K · Jun 18, 2025 Risk: low
  Sinovac Biotech Ltd. filed a Form 6-K on June 18, 2025, to report its activities for the month of June 2025. The filing includes a signature from Dr. Chiang Li,
• Sinovac Biotech Ltd. Files May 2025 6-K Report — 6-K · May 23, 2025 Risk: low
  Sinovac Biotech Ltd. filed a Form 6-K on May 23, 2025, to report its activities for the month of May 2025. The filing indicates the company's principal executiv
• Sinovac Biotech Ltd. Calls Special Shareholder Meeting — 6-K · May 20, 2025 Risk: low
  Sinovac Biotech Ltd. announced on May 19, 2025, that it disseminated a notice for a special meeting of its shareholders. Shareholders of record as of May 19, 20
• Sinovac Biotech Director Resigns — 6-K · May 19, 2025 Risk: low
  On May 16, 2025, Sinovac Biotech Ltd. announced the resignation of Mr. Pengfei Li from its board of directors, effective immediately. Mr. Li's departure does no
• Sinovac Biotech Ltd. Files April 2025 6-K Report — 6-K · Apr 30, 2025 Risk: low
  Sinovac Biotech Ltd. filed a Form 6-K on April 30, 2025, for the month of April 2025. The filing is a report of a foreign private issuer and indicates that the
• Sinovac Biotech Accountant Resigns, Opinions Unreliable — 6-K · Apr 21, 2025 Risk: high
  On April 15, 2025, Sinovac Biotech Ltd. received notification from Grant Thornton Zhitong Certified Public Accountants LLP that they are resigning as the Compan
• Sinovac Biotech Ltd. Files April 2025 6-K Report — 6-K · Apr 1, 2025 Risk: low
  Sinovac Biotech Ltd. filed a Form 6-K on April 1, 2025, reporting for the month of April 2025. The filing is a report of a foreign private issuer and includes a
• Sinovac Biotech Ltd. Files March 2025 6-K Report — 6-K · Mar 31, 2025 Risk: low
  Sinovac Biotech Ltd. filed a Form 6-K on March 31, 2025, reporting for the month of March 2025. The filing includes a press release as Exhibit 99.1. The company
• Sinovac Biotech Files February 2025 Report — 6-K · Feb 28, 2025 Risk: low
  Sinovac Biotech Ltd. filed a Form 6-K on February 28, 2025, to report its activities for the month of February 2025. The filing includes a press release as Exhi
• Sinovac Biotech Files 6-K Report — 6-K · Jan 16, 2025 Risk: low
  Sinovac Biotech Ltd. filed a Form 6-K report on January 16, 2025, for the month of January 2025. The report is a routine filing for a foreign private issuer and
• SAIF Partners IV L.P. Amends Sinovac Biotech Holdings Filing — SC 13D/A · Sep 12, 2024 Risk: medium
  SAIF Partners IV L.P. filed an amendment (No. 13) to its Schedule 13D on September 12, 2024, regarding its holdings in Sinovac Biotech Ltd. The filing indicates
• Sinovac Biotech Ltd. Files August 2024 6-K Report — 6-K · Aug 16, 2024 Risk: low
  Sinovac Biotech Ltd. filed a Form 6-K on August 16, 2024, to report its activities for the month of August 2024. The filing includes a signature by Nan Wang, Ch
• SAIF Partners IV L.P. Amends Sinovac Biotech Stake Filing — SC 13D/A · Jun 17, 2024 Risk: medium
  SAIF Partners IV L.P. has amended its Schedule 13D filing regarding Sinovac Biotech Ltd. as of June 17, 2024. The filing indicates a change in the beneficial ow
• Sinovac Biotech Ltd. Files 6-K Report — 6-K · Apr 30, 2024 Risk: low
  Sinovac Biotech Ltd. filed a Form 6-K on April 30, 2024, for the month of April 2024. The filing was signed by Nan Wang, Chief Financial Officer, on April 29, 2
• Sinovac Biotech Ltd. Files 20-F Annual Report for Fiscal Year 2023 — 20-F · Apr 29, 2024 Risk: medium
  SINOVAC BIOTECH LTD (SVA) filed a Foreign Annual Report (20-F) with the SEC on April 29, 2024. Sinovac Biotech Ltd. filed its 20-F annual report for the fiscal
• SC 13G/A Filing — SC 13G/A · Mar 20, 2024
• Sinovac Biotech Files Fifth Amendment on Feb 21, 2024 — 6-K · Feb 21, 2024 Risk: medium
  On February 21, 2024, Sinovac Biotech Ltd. (the "Company") filed a Form 6-K with the SEC, indicating it entered into a fifth amendment. This filing, under Commi

Frequently Asked Questions